D-0523-2026 Class II Ongoing

Recalled by Acella Pharmaceuticals, LLC — Alpharetta, GA

FDA drug recall D-0523-2026 was initiated by Acella Pharmaceuticals, LLC on Apr 20, 2026 and is designated Class II. Reason for recall: Chemical contamination; presence of lead and lithium above specification The recall status is ongoing. Affected quantity: 6,336 bottles.

Recall details

Product Type
Drugs
Report Date
May 13, 2026
Initiation Date
Apr 20, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6,336 bottles

Product description

NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16

Reason for recall

Chemical contamination; presence of lead and lithium above specification

Distribution pattern

Nationwide

Code information

Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0523-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0523-2026. Report a data issue: hello@regdatalab.com.